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1. Introduction 
1.1 Prevalence & incidence  
The population prevalence of vitiligo ranges from 0.1% to 2% and shows a wide 
variability among ethnic groups (Bolognia et al., 1998; Hann and Nordlund, 2000). 
Whereas the estimated population prevalence of vitiligo is approximately 0.38% for 
Caucasians in the United States and Northern Europe (Howitz et al., 1977), vitiligo affects 
0.19% of the population in China (Xu et al., 2002). Other international studies show that 
the incidence of vitiligo ranges from 0.1 to over 8.8% (Srivastava, 1994; Schwartz and 
Janniger, 1997; Hann et al., 1997; Kovacs, 1998; Agarwal, 1998; Handa and Kaur, 1999; 
Alkhateeb et al., 2003). The highest incidence of the condition has been recorded in 
Indians from the Indian subcontinent, followed by Mexico and Japan (Table 1). The 
difference in its incidence may be due to higher reporting of vitiligo in a population, 
where an apparent color contrast and stigma attached to the condition may force patients 
to seek early consultation (Panja, 1947; Levai, 1958; Punshi and Thakre, 1969; Behl and 
Bhatia, 1971; Sehgal, 1974; Koranne and Sachdeva, 1988; El Mofty, 1968; Grunnet et al., 
1970; Dawber, 1968; Perrot, 1973; Fornara, 1941; Canizares, 1960; Ruiz Maldonnado et al., 
1977; Fitzpatrick, 1974; Arakawa, 1941; Khoo, 1962). 
Vitiligo is reported more frequently in females than males, which may be the result of 
increased reporting rates in females due to greater social consequences in females affected 
by vitiligo (Kovacs, 1998; Lee Poole and Boissy, 1997; Hann and Lee, 1996; Zaima and Koga, 
2002; Jeninger, 1993; Halder, 1997; Cho et al., 2000; Handa and Dogra, 2003). 
Adults and children of both sexes are equally affected; however, the majority of the vitiligo 
cases are reported during stages of active development. About 50% of patients present 
before the age of 20 and nearly 70-80% present before 30 years of age. Although no age is 
immune to vitiligo, the disease is very rarely observed at birth (Behl et al., 2003; Jaigirdar et 
al., 2002; Engel, 2001; Lerner, 1999; Gauthier et al., 2003; Westerhof et al., 1996).  
The proportion of patients with a positive family history varies from one part of the world 
to another, with particularly wide ranges reported in India (6.25-18%), with reports of up to 
40% elsewhere in the world (Behl et al., 2003).  
www.intechopen.com
 
Vitiligo – Management and Therapy 18
Author(s) Year 
City/ or 
Region/Country/Continent 
Incidence (%) 
    
El Mofty  1968 Egypt/Africa 1 
Panja  
Levai  
1947 
1958 
Calcutta/India/Asia 
Vellore/India/Asia 
6 
4 
Punshi & Thakre  1969 Amrawati/India/Asia  8 
Behl & Bhatia  
Sehgal  
Koranne &Sachdeva  
Howitz et al. 
Grunnet et al. 
Dawber  
Perrot  
Fornara  
Canizares  
 Ruiz-Maldonnado  
Fitzpatrick  
 
Arakawa 
 
Khoo  
  
1972 
1974 
1988 
1977 
1970 
1968 
1973 
1941 
1960 
1977 
1974 
 
1941 
 
1962 
Delhi/India/Asia 
Goa/India/Asia 
Delhi/India/Asia` 
Denmark/Europe 
Denmark/Europe 
England/Europe 
France/Europe 
Italy/Europe 
Mexico/North America 
Mexico/North America 
Massachusetts/United 
States/North America 
Japan/Asia 
 
Malaysia/Asia 
8.8 
2.9 
1.25 
0.38 
1.44 
0.15 
3.0 
0.3 
4 
2.6 
8 
 
1.64 
 
0.7 
    
 
Table 1. Vitiligo: Global Incidence Patterns 
2. Epidemiology of vitiligo: A worldwide survey 
Numerous studies have been conducted around the world concerning the epidemiological 
characteristics of vitiligo, in particular the racial, ethnic, and cultural differences in its 
prevalence. 
2.1 Europe 
2.1.1 Denmark 
The prevalence of vitiligo was 0.38% in a representative population of 47,033 in Denmark. 
Both sexes were found to be equally affected, with no significant difference found in the 
distribution of vitiligo patients among five different municipalities or between urban and 
rural districts. New cases of vitiligo steadily increased with advancing age, its onset being 
most often between the ages of 40 and 60 years of age. The age-specific prevalence 
increased from 0.09% in patients under the age of 10 to 0.9% in the age group between 60 to 
69 years. It was suggested that these characteristics of vitiligo in Denmark would also apply 
to northwest Europe (Howitz et al., 1977). 
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2.1.2 United Kingdom 
The characteristics of vitiligo in 41 adults presenting to a university dermatology clinic in 
Sheffield, United Kingdom were studied in a case review. Of 41 patients, there were 29 
women (70.7%) and 12 men (29.3). The authors reported an age of onset before 20 years in 
41.5% of patients (n=17), while the mean was 28 years. The oldest age of onset was 74 years. 
In these patients, the average duration of disease was 16 years. Autoimmune thyroid disease 
was present in 34.1% of cases (n=14). Only 17% (n=7) gave a family history of vitiligo 
(Mason and Gawk Rodger, 2005). 
2.2 Middle East 
2.2.1 Saudi Arabia: Qassim region 
Alzolibani found that in a random sampling of vitiligo patients in the Qassim region of 
Saudi Arabia, approximately one-third of cases were positive for parental consan`guinity.  
A particularly high first-cousin consanguinity was noted in this study, which was found to 
be higher than that reported among the general Saudi population (22.5% vs. 19.5%) 
(Alzolibani, 2009; El-Hazmi et al., 1995). 
Moreover, a positive family history was obtained in 56.8% of families studied, 57.1% of them 
having two or more affected relatives. The age of onset of vitiligo was 31 years in familial 
cases and 33 years in non-familial controls. Vitiligo occurred before the age of 20 in 19% of 
family cases and in 36% of non-familial controls. Most families (75%) had no more than two 
affected members. 
As observed in this study, the incidence rate of vitiligo in relatives increased with a closer 
blood relationship to probands, which is indicative of the significant familial aggregation of 
vitiligo noted in a number of previous studies (Nath et al., 1994; Majumder et al., 1988). The 
proband cases in this study showed higher relative risks among their first- and second-
degree relatives, but not as high among their third-degree relatives. 
Inheritance pattern prediction using the frequency of vitiligo among siblings in relation to 
the general population coincided with the multifactorial model particularly for the vitiligo 
vulgaris subtype followed by the acrofacial subtype, and least in the focal subtype. 
Calculation of heritability showed a high weighted mean of 0.54. 
Similar data from China supports these findings (Sun et al., 2006).  
Genetic factors play a relatively important role in the evolution of vitiligo among subjects in 
the Qassim region. Recognition of this could have a potential impact on disease prevention 
through family counseling and other forms of intervention.  
2.2.2 Kuwait 
In a sample of 88 pediatric vitiligo patients at a hospital dermatology clinic, the age of onset 
was between 8 and 12 years in 51% of these patients (Al-Mutairi et al., 2005). A positive 
family history was obtained in 27.3% of the patients. Vitiligo vulgaris was the most common 
clinical type observed. Three patients, though clinically asymptomatic, incidentally had anti-
thyroid antibodies, which are comparable to results published previously.  
Eighty Korean children (ages 8 months-12 years) with clinical and/or histopathologic 
diagnoses of vitiligo were evaluated; :39 boys and 41 girls. The mean age at first visit was 7.9 
years and the mean age at disease onset was 5.6 years. The children were compared with a 
control group of 422 adults with vitiligo. Children comprised 16% of the total vitiligo 
patients and adults comprised 84%. A family history of vitiligo was found in 11 (13.8%) of 
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children, compared to 10.7% in the adult group. ; pPoliosis was found in 20 (25%) of 
children. H; halo nevi was found in 2 (2.5%) of children, compared to 4% in the adult group; 
combined autoimmune and endocrine diseases were noted in in 1 (1.3% of children), 
compared to 7.6% in the adult group; and segmental vitiligo in 26 (was diagnosed in 32.5% 
of children), compared to 13.0% inof the adult group. TheVitiligo and its associated 
conditions were combined diseases were significantly less often frequentfound in children 
compared tothan adults (p < 0.01), and segmental vitiligo was found in significantly higher 
numbers of children than the adult patientsmore often associated with children (p < 0.0001). 
Thise study does id not show a higher prevalence of vitiligo in girls as reported in other 
studies, which may indicate a racial differencetrait (Cho et al., 2000). 
2.3 Indian subcontinent 
2.3.1 India 
In India, the incidence of vitiligo was reported to be between 1- 2 % (Majumder et al., 1988). 
In a large population-based study of vitiligo patients (n=998), 43% were male (n=429) and 
(57%) were females (n=569). The mean age at onset for males was found to be 23.3 years and 
for females was 17.4 years. The median age at onset in males was 18 years and 13.6 years in 
females. The earliest age at onset was found to be at birth and the oldest was 73 years 
(Tawade et al., 1997).Out of 998 cases, 272 (27.3%) had one or more relatives with vitiligo. 
Among these, 207 (76.1%) cases had only one relative affected whereas 65 (28%) cases had 
more than one relative with vitiligo.  
The slightly higher prevalence in females may not be the true situation, as only self- 
reported cases were enlisted in the study. Due to the social stigma of vitiligo in the 
community, young females tend to report earlier due to matrimonial anxiety. The age at 
onset is consistent with previous studies (Mosher et al., 1987). Onset at birth is not so 
common. In the present study 3 cases had onset of vitiligo at birth, of which One infant's 
mother had vitiligo. The peak incidence between 5-14 years may reflect concerns about 
cosmetic disfigurement in this age group and parental anxiety leading to early reporting.  
In another Indian study (Handa and Kaur, 1999), 1,436 patients were seen between 1989 and 
1993. Males constituted 54.5% of the group and females, 45.5%. Mean age of the patients was 
25 years, and average disease duration at the time of hospital visit was 3.7 years. 
Leukotrichia was present in 165 (11.5%), and Koebner's phenomenon was observed in 72 
(5.0%). Twenty-nine (2%) patients had associated halo nevi. A family history of vitiligo was 
reported in 165 (11.5%) patients.  
A study was performed in a military service hospital patient population utilizing 120 
cases of vitiligo (Kar, 2001). The youngest patient in this series was a 2 year-old girl and 
oldest patient was 65 year old male. In 52 (43.2%) patients, disease started before the age 
of 20. The duration of disease varied from 2 months to ten years. Eight patients (6.6%) 
reported a family history of vitiligo. In one case, a mother and her two daughters had 
vitiligo. The male -to -female ratio in vitiligo was observed in this study to be nearly 
equal, meaning thereby this disease had no predilection for any gender. Similar 
observations were also noted by various researchers (Sarin and Kumar, 1977; Behl et al., 
1961). Furthermore, the incidence of vitiligo was 43.2% in the age group of 20 years of age 
and younger, as compared to an incidence of 9.9% in individuals over 40 years of age. 
Universal vitiligo was found in 2 (1.6%) cases and both had a positive family history of 
disease. Other studies found a positive family history in 6.25-10% of cases (Sarin and 
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Kumar, 1977; Behl et al., 1961). The results of this study may indicate that the mode of 
vitiligo transmission may be caused by an autosomal dominant gene with variable 
penetrance (Ando et al., 1993; Behl et al., 1994). 
In an Indian pediatric population (Handa and Dogra, 2003), 625 children with vitiligo 
were seen over 10 years: 357 (57.1%) were girls and 268 (42.9%) were boys. As compared 
to adult patients with vitiligo, this sex difference was found to be statistically significant 
(p < 0.001). The mean age of onset of the disease was 6.2 years. Leukotrichia was present 
in 77 patients (12.3%), while Koebner phenomenon was observed in 71 patients (11.3%). 
Halo nevi were observed in 29 patients (4.4%). Seventy-six patients (12.2%) had a family 
history of vitiligo.  
A total of 365 patients were included in a study that focused on the clinical and 
sociodemographic aspects of vitiligo. There was a female preponderance of disease: 
females (68.4%) were found to be more affected than males (31.6%), in a ratio of 2.1:1 
(Shah et al., 2008). The majority (32.82%) of the patients were in their second decade of 
life, and 58.63% of the patients were unmarried. A positive family history was present in 
50 (13.7%) of patients, and first-degree relatives were affected in 35 of these patients. 
Vitiligo has a polygenic or autosomal dominant inheritance pattern with incomplete 
penetrance and variable expression (Bleehen et al., 1992; Moscher et al., 1993; Bolognia 
and Pawelek, 1988). Familial occurrence has been reported to be in the range of 6.25% to 
30% (Shajil et al., 2006). Positive family history is considered to be a poor prognostic factor 
for vitiligo. 
The female-to-male ratio in this study was 2.1:1, which was different from other study 
findings (Handa and Kaur, 1999; Koranne et al., 1986). Most reports showed that males and 
females were affected with almost equal frequency, but females outnumbered males in this 
study presumably because of social stigma and the marital concerns which prompt women 
to seek early consultation. In 54.5% of the patients, the age at onset was in the first or second 
decade of life, consistent with most reports from India and the West.  
2.3.2 Mumbai 
In Mumbai, India, records of 33,252 new patients attending a dermatology outpatient 
department from June 2002 to June 2008 were analyzed for the presence of vitiligo 
(Poojary, 2011). 
The total number of vitiligo patients was 204. The male: female proportion was almost 
equal. A family history of vitiligo was seen in 3.43% of cases. Associated autoimmune 
disorders were seen in 2.94% of cases and were mainly skin associated autoimmune diseases 
(morphea, alopecia areata, discoid lupus erythematosus, and pemphigus erythematosus), 
except for one case of Grave's disease. This may indicate that the association of vitiligo with 
other autoimmune diseases emphasizes the autoimmune etiology of vitiligo, and also the 
need to actively look for, and if necessary, investigate patients with vitiligo for other 
autoimmune diseases. 
2.3.3 Calcutta 
An epidemiological profile of vitiligo in Calcutta was gathered from 15,685 individuals 
drawn from the general population; pedigree data was collected from 293 vitiligo patients. 
The overall prevalence of vitiligo was about 5 per 1,000 individuals. There were no 
significant sex or age differences. About a 4.5-fold increase in prevalence was observed 
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among close biological relatives of affected individuals. There were no significant 
differences in the frequencies of various types of vitiligo between probands with and 
without positive family history. The overall mean and modal ages of onset were about 22 
years and 15 years, respectively. The mean ages among males (24.8 years) and females (19.3 
years) were significantly different (Das et al., 1985). 
2.4 Africa 
2.4.1 Tunisia 
In a retrospective study of patients attending a Tunisian outpatient dermatological practice 
(Zeglaoui et al., 1985), 503 patients were reviewed from a 5-year period. There were 288 
women (57.3%) and 215 (42.7%) men (F: M = 1.33). The average age was 28.2 years (3- 80 
years). The peak of frequency was located in the second decade of the life (26%). A family 
history of vitiligo was found in 27% of cases. The average time of until initial consultation 
was 21 months. An association with other pathological conditions was found in 23% of cases 
which is consistent with available literature. 
2.4.2 Nigeria 
To investigate vitiligo in the Nigerian Africans, 351 patients with vitiligo, representing 3.2% 
of new dermatologic cases at a study wsite, were enrolled (Onunu and Kubeyinje, 2003). The 
study group was made up of 153 males (43.6%) and 198 females (56.4), giving a sex ratio of 
1: 1.3. The peak incidence of vitiligo was in the second and third decades of life. There was a 
positive family history of vitiligo in 18% of subjects.  
2.5 Caribbean 
2.5.1 French West Indies: Isle of Martinique 
A study was conducted in an academic dermatology clinic which analyzed a cohort of 2,077 
dermatology outpatients. There was a vitiligo prevalence rate of 0.34%, with a 
predominance of affected females. The median age at onset was 29 years. Of the vitiligo 
patients, over 30% had a family history of vitiligo, 6% (n=2) had concurrent thyroid disease, 
6% (n=2) had psoriasis, and 3% (n=1) had atopic dermatitis. These findings are comparable 
to data in Caucasian populations (Boisseau-Garsaud et al., 2000). 
2.6 North America 
2.6.1 United States 
Data on 160 Caucasian families living in the United States was collected based on primary 
probands with vitiligo (Majumder et al., 1993). The rate at which first degree relatives were 
also afflicted with vitiligo is 20%. Children of probands were found to have 1.7 times the 
risk of vitiligo compared to other first-degree relatives. The relative risk (RR) for vitiligo was 
approximately 7 for parents, 12 for siblings, and 36 for children. For second-degree relatives, 
the RR varied between 1 and 16. The pattern of the relationship between RR and degree of 
kinship indicates the involvement of genetic factors, although it is not consistent with single-
locus Mendelian transmission. 
In general, patients with vitiligo who have an family history of vitiligo are more likely to 
have an earlier age of onset of disease than those with a negative family history (odds 
ratio = 3.70, P = .024). There was found to be no association between family history and 
site of onset, distribution, or course of disease. Onset of pediatric vitiligo also seemed to 
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be linked to a family history of vitiligo. This suggests that awareness of this association 
can allow for earlier detection and initiation of treatment (Pajvani et al., 2006). 
3. Genetic heritability of vitiligo 
3.1 Familial aggregation of vitiligo and relationship with autoimmune diseases 
Familial aggregation of vitiligo was noted as early as 1933 (Majumder, 2000), suggesting that 
genetic factors might have an important effect on the development of vitiligo (Hafez et al., 
1983). Although vitiligo aggregates in families, it does not appear to segregate in a simple 
Mendelian pattern (Majumder et al., 1993; Kim et al., 1997; Nordlund and Majumder, 1997). 
Previously, an autosomal recessive model of vitiligo that took the variability of the age of 
onset into account was proposed, suggesting that there might be genes at three or four 
autosomal loci controlling vitiligo (Alkhateeb et al., 2002; Majumder et al., 1988). This was 
supported by the high frequency of vitiligo and other autoimmune diseases in isolated 
inbred communities. On the other hand, the actual onset of vitiligo in genetically susceptible 
individuals seems to require exposure to environmental triggers (Nath et al., 1994; Birela et 
al., 2008). Attempts to identify genes involved in vitiligo susceptibility have involved gene 
expression studies, allelic association studies of candidate genes, and genome-wide linkage 
analyses to discover new genes (Zhang et al., 2008). 
Most evidence indicates that generalized vitiligo is an organ-specific autoimmune disease 
directed against melanocytes (Ongenae et al., 2003; Rezaei et al., 2007), and indeed about 
20% of vitiligo patients (and their close relatives) manifest concomitant occurrence of other 
autoimmune diseases, particularly autoimmune thyroid disease, rheumatoid arthritis, late-
onset type I diabetes mellitus, psoriasis, pernicious anemia, systemic lupus erythematosus, 
and Addison’s disease (Alkhateeb et al., 2003 ). Nevertheless, heritable biological properties 
of the melanocyte or other factors, combined with environmental triggers, may contribute to 
loss of immune tolerance and ultimately autoimmunity directed against melanocytes 
(Boissy and Spritz, 2009). Family clusters of vitiligo cases are not uncommon, occurring in a 
non-Mendelian pattern suggestive of polygenic, multifactorial inheritance. Probands’ first-
degree relatives have 6–7% risk of developing generalized vitiligo, and the concordance rate 
in monozygotic twins is 23%.  
Genetic linkage and association studies have implicated a number of genes in vitiligo 
pathogenesis, especially genes involved in immune function (Spritz, 2007; Spritz, 2008). 
However, these loci account for a relatively small fraction of total disease liability. Genetically 
isolated ‘‘founder populations’’ afford special opportunities to identify genes involved in 
susceptibility to disease, as founder populations may have elevated prevalence of specific 
diseases and reduced heterogeneity of causal genetic and environmental risk factors compared 
with more outbred populations (Wright et al., 1999). Accordingly, susceptibility alleles that 
represent relatively minor genetic risk factors for complex diseases in the general population 
may become amplified and constitute major risk alleles in a founder population, and thus may 
be localized using less dense maps and smaller sample sizes than similar studies conducted in 
more outbred populations (Wittke-Thompson et al., 2007).  
3.2 Genetic basis of vitiligo 
Genes play a role in all aspects of vitiligo pathogenesis, even in response to environmental 
triggers. Typical generalized vitiligo behaves as a “complex trait”, meaning it is a polygenic, 
multifactorial disease involving multiple genes and non-genetic factors. Only a few vitiligo 
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susceptibility genes have been identified with reasonable certainty. These include human 
leukocyte antigen (HLA), protein tyrosine phosphatase, non-receptor type 22 (PTPN22), 
and, NACHT, LRR and PYD domains-containing protein 1 (NALP1), all genes associated with 
autoimmune susceptibility. Cytotoxic lymphocyte antigen 4 (CTLA4) is also under 
investigation (Spitz, 2008).  
The earliest evidence suggesting a genetic basis for vitiligo was its association with a 
number of other autoimmune disorders known to have heritable predispositions, such as 
type 1 diabetes mellitus. Furthermore, genetic diseases are substantially more prevalent in 
children of parents who are close relatives. In an Indian study of a community with a 
predominance of consanguineous marriages, 20% of individuals had vitiligo (Ramaiah et al., 
1988). Significantly earlier onset has been observed when there is a family history of vitiligo 
(24.8 vs. 42.2 years of age) (Hann and Lee, 1996).  
Genetic models suggested by analysis of family studies include a multifactorial model 
(Goudie et al., 1983), a dominant model with incomplete penetration (Hafez et al., 1983), and 
a multilocular recessive model (Majumder et al., 1988). There may also be two coexisting 
modes of inheritance for vitiligo depending on age of onset (Arcos-Burgos et al., 2002). In 
patients with early onset vitiligo (before the age of 30), vitiligo inheritance most closely 
follows a dominant mode of inheritance with incomplete penetration. However, a 
predisposition for vitiligo resulting from a recessive genotype and exposure to certain 
environmental triggers appears to explain the inheritance pattern of late onset vitiligo (after 
30 years of age). Specific HLA haplotypes are strongly associated with family history of 
vitiligo, severity of disease, age of onset, and population geography (Zamani et al., 2001; 
Ando et al., 1993; Finco et al., 1991). Gene polymorphisms in the major histocompatibility 
complex (MHC) Class II region of the HLA locus have been previously found to be 
associated with other autoimmune diseases, such as type 1 diabetes mellitus and juvenile-
onset rheumatoid arthritis (Deng et al., 1995; Prahalad et al., 2001). The HLA genes encoding 
both the transporter associated with antigen-processing (TAP1) and subunits of the 
immunoproteasome latent membrane protein 2 and 7 (LMP2/LMP7) have been found to be 
associated with vitiligo of early onset in Caucasian patients (Casp et al., 2003).  
The (CTLA-4) gene encodes a protein involved in the inhibition of improperly-activated T-
cells. CTLA-4 variants have been linked to numerous autoimmune diseases. There is an 
association between the CTLA-4 polymorphism and the occurrence of vitiligo with other 
autoimmune comorbidities (Blomhoff et al., 2005). Catechol-O-methyl transferase (CTLA-4) 
is an enzyme that plays a major role in the metabolism of toxic or biologically active drugs, 
neurotransmitters and metabolites. One such metabolite, O-quinones, can be formed during 
melanin synthesis in the absence of adequate CTLA-4 activity. A CTLA-4 polymorphism has 
been found to be significantly associated with acrofacial vitiligo (Tursen et al., 2002).  
Chromosome 1p31, termed the autoimmune susceptibility locus (AIS1), has been found to 
be associated to a highly significant degree with generalized vitiligo in Caucasians living 
in North American and the United Kingdom (Fain et al., 2003). Reduced activity of the 
VIT1 gene, located on chromosome 2p16, has been associated with increased susceptibility 
to vitiligo, possibly as a result of dysfunction of melanocyte nucleotide mismatch 
repair(Lee Poole, 2001). 
A genome-wide association study of generalized vitiligo in an isolated European founder 
population identified a significant association of single-nucleotide polymorphisms in a block 
on band 6q27, in close vicinity to IDDM8, which is a linkage and an association signal for 
type I diabetes mellitus and rheumatoid arthritis. Only one gene, SMOC2, is in the region of 
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association, within which single-nucleotide polymorphism (SNP) rs13208776 attained 
genome-wide significance for association with other autoimmune diseases and vitiligo 
(Birlea et al., 2009).  
Genetic risk for vitiligo is well-supported by multiple lines of evidence. Vitiligo is frequently 
associated with familial clustering (Alkhateeb et al., 2003; Goudie et al., 1983; Mehta et al., 
1973; Carnevale et al., 1980). Approximately 20% of probands have at least one affected first 
degree relative. The risk of first degree relatives of patients with vitiligo for developing the 
disease is elevated by 7- to 10-fold compared to the general population (Alkhateeb et al., 
2003; Sun et al. 2006).  
In addition, segregation analysis suggests that vitiligo is a multifactorial and polygenic 
disorder that likely results from multiple genetic and environmental factors (Alkhateeb et 
al., 2003; Arcos-Burgos et al., 2002; Nath et al., 2001; Spritz et al., 2004). However, no disease 
genes have been identified for vitiligo thus far. Several genome-wide linkage analyses of 
vitiligo have been performed in the past few years, and multiple linkages to vitiligo have 
been identified (Alkhateeb et al., 2002; Fain et al., 2003; Spritz et al., 2004). Co-segregation of 
systemic lupus erythematosus and vitiligo in European American pedigrees revealed 
significant linkage on 17p13 (Nath et al., 2001). Another co-segregation of vitiligo and 
Hashimoto thyroiditis identified a candidate gene with highly significant linkage at a locus ( 
“AIS1”) on chromosome 1p32.2-p31.3 (Alkhateeb et al., 2002; Spritz et al., 2004), as well as 
additional linkage evidence on chromosomes 1, 7, 8, 11, 19, and 22 (Spritz et al., 2004). There 
are confirmed linkage findings on chromosomes 7q and 8p (AIS2 and AIS3) (Nath et al., 
2001). The linkage evidence at the AIS1, AIS2, and systemic lupus erythematosus, vitiligo-
related 1 (SLEV1) loci was mainly from autoimmunity-associated families, while the 
evidence at the AIS3 locus was primarily from non-autoimmunity-associated families, 
suggesting that generalized vitiligo may be divided into two distinct phenotypic 
subcategories that involve different disease loci or alleles.  
4. Conclusion 
Vitiligo is a common, acquired, discoloration of the skin. Most studies show that vitiligo is 
common in the younger age group, with females of reproductive age forming the major 
group. Genetic factors play a relatively important role in the evolution of vitiligo. The extent 
of familial aggregation of vitiligo is statistically significant. The genetic model of vitiligo 
may be consistent with a polygenetic or multifactorial inheritance in a dominant gene 
pattern. 
5. References 
Agarwal G. Vitiligo: An under-estimated problem. Fam Pract 1998;15:519-23. 
Akay BN, Bozkir M, Anadolu Y, Gullu S. Epidemiology of vitiligo, associated autoimmune 
diseases and audiological abnormalities: Ankara study of 80 patients in Turkey. J 
Eur Acad Dermatol venereal. 2010 Oct;24(10):1144-50.  
Alkhateeb A, Fain PR, Thody A, Bennett DC, Spritz RA. Epidemiology of vitiligo and 
associated autoimmune diseases in Caucasian probands and their families. 
Pigment Cell Res 2003;16:208-14. 
www.intechopen.com
 
Vitiligo – Management and Therapy 26
Alkhateeb A, Stetler GL, Old W, Talbert J, Uhlhorn C, Taylor M, et al. Mapping of an 
autoimmunity susceptibility locus (AIS1) to chromosome 1p31.3–p32.2. Hum Mol 
Genet. 2002; 11:661–7. 
Al-mutairi N, Sharma AK, Al-Sheltawy M, Nour-Eldin O. Childhood vitiligo: a prospective 
hospital-based study. Australas J. 2005 Aug;46(3):150-3. 
Alzolibani A. Genetic epidemiology and heritability of vitiligo in the Qassim region of Saudi 
Arabia. Acta Dermatovenerol Alp Panonica Adriat. 2009 Sep;18(3):119-25. 
Ando-I, Chi-HI, Nakagawa H, et al. Differences in clinical features and HLA antigens 
between familial and non familial vitiligo of non segmental type. Br J Dermatol 
1993; 123:408-410. 
Arakawa A. Quoted by Robert P. Uber die Vitiligo, Dermatologica 1941;84:257-319. 
Arcos-Burgos M. Parodi E. Salgar M. Bedoya E. Builes J. Jaramillo D. Ceballos G. Uribe A. 
Rivera N. Rivera D. Fonseca I. Camargo M. Palacio G. Vitiligo: complex 
segregation and linkage disequilibrium analyses with respect to microsatellite loci 
spanning the HLA. Hum Genet 2002; 110: 334-42. 
Arycan O, Koc K, Ersoy L. Clinical characteristics in 113 Turkish vitiligo patients. Acta 
dermatovenerol Alp Panonica Adriat. 2008 Sep; 17(3):129-32. 
Behl PN, Agarwal RS, Singh G. Etiological studies in vitiligo and therapeutic response to 
standard treatment. Indian J Dermatol 1961;6:101. 
Behl PN, Aggarwal A, Srivastava G. Vitiligo In : Behl PN, Srivastava G, editors. Practice of 
Dermatology. 9 th ed. CBS Publishers: New Delhi; 2003. p. 238-41. 
Behl PN, Bhatia RK. 400 case of vitiligo - A clinico therapeutic analysis. Indian J Dermatol 
1971;17:51-4. 
Behl PN, Kotia A, Sawal P. Vitiligo: Age group related trigger factor and morphological 
variants. Indian J Dermatol Venereol Lepr 1994;60: 275-279. 
Birlea SA, Fain PR, Spritz RA. A Romanian population isolate with high frequency of vitiligo 
and associated autoimmune diseases. Arch Dermatol. 2008 Mar;144(3):310–6. 
Birlea SA, Gowan K, Fain PR, Spritz RA. Genome-Wide Association Study of Generalized 
Vitiligo in an Isolated European Founder Population Identifies SMOC2, in Close 
Proximity to IDDM8. J Invest Dermatol. Nov 5 2009. 
Bleehen SS, Ebling FJ, Champion RH. Disorders of skin color. In : Champion RH, Burton JL, 
Ebling FJ, editors. Text book of Dermatology. London: Blackwell Scientific 
Publications; 1992. p. 1561-622. 
Blomhoff A. Helen Kemp E. Gawkrodger DJ. Weetman AP. Husebye ES. Akselsen HE. Lie 
BA. Undlien DE. CTLA4 polymorphisms. Pigment Cell Res 2005; 18: 55-8. 
Boisseau-Garsaud AM, Garsaud P, Cales-Quist D, Helenon R, Queneherve C, Clair RC. 
Epidemiology of vitiligo in the French West Indies (Isle of Martinique). Int J 
Dermatol. 2000 Jan;39(1):18-20. 
Boissy RE, Spritz RA (2009) Frontiers and controversies in the pathobiology of vitiligo: 
separating the wheat from the chaff. Exp Dermatol 18:583–5 
Bolognia JL, Nordlund JJ, Ortonne J-P (1998) Vitiligo vulgaris.In: Nordlund JJ, Boissy RE, 
Hearing VJ, King RA, Ortonne J-P (eds) The pigmentary system. Oxford 
UniversityPress, New York, pp 513–551. 
Bolognia JL, Pawelek JM. Biology of hypopigmentation. J Am Acad Dermatol 1988;19:217-
55. 
www.intechopen.com
 
Genetic Epidemiology and Heritability of Vitiligo 27 
Canizares O. Geographic dermatology: Mexico and Central America. Arch Dermatol 1960; 
82: 870-93. 
Carnevale A, Zavala C, Castillo VD, Maldonado RR, Tamayo L (1980) Analisis genetico de 
127 families con vitiligo. Rev Invest Clin 32:37–41. 
Casp CB. She JX. McCormack WT. Genes of the LMP/TAP cluster are associated with the 
human autoimmune disease vitiligo. Genes Immun 2003; 4: 492-9. 
Cho S, Kang KC, Hahm JH. Characteristics of vitiligo in Korean children. Pediatr Dermatol 
2000;17:189-93. 
Das SK, Majumder PP, Chakraborty R, Majumdar TK, Haldar B. Studies on vitiligo. I. 
Epidemiological profile in Calcutta, India. Genet Epidemiol. 1985; 2(1):71-8. 
Dawber RP. Vitiligo in Mature onset diabetes mellitus. Br J Dermatol 1968;80:275-8. 
Deng GY. Muir A. Maclaren NK. She JX. Association of LMP2 and LMP7 genes within the 
major histocompatibility complex with insulin-dependent diabetes mellitus: 
population and family studies. Am J Hum Gen 1995; 56: 528-34. 
El Mofty AM. Vitiligo and psoralens. Pergamon Press: Oxford; 1968. p. 1147-95. 
El-Hazmi MA, Al-Swailem A R, Warsy A S, Al-Swailem A M, Sulaimani R, Al-Meshari A A. 
Consanguinity among the Saudi Arabian population. J Med Genet. 1995 August; 
32(8): 623–6. 
Engel L. What are those white patches in my patient's skin? Dermatol Nurs 2001;13:292-7.  
Fain PR, Gowan K. LaBerge GS. Alkhateeb A. Stetler GL. Talbert J. Bennett DC. Spritz RA. A 
genome-wide screen for generalized vitiligo: confirmation of AIS1 on chromosome 
1p31 and evidence for additional susceptibility loci. Am J Hum Gen 2003; 72: 1560-4. 
Finco OM, Cuccia M, Martinetti G, Ruberto G, Orecchia G, Rabbiosi G. Age of onset in 
vitiligo: relationship with HLA supratypes. Clin Genet 1991; 39: 48-54. 
Fitzpatrick TB. Phototherapy of vitiligo, in sunlight and man. Normal and abnormal biologic 
response. In : Pathak MA, editor. University of Tokyo Press: Tokyo; 1974. p. 783-91. 
Fornara I. Quoted by Robert P. Uber die vitiligo. Dermatologica 1941;4:241-319. 
Gauthier Y, Cario-Andre M, Lepreux S, Pain C, Taieb A. Melanocyte detachment after skin 
friction in non lesional skin of patients with generalized vitiligo. Br J Dermatol 
2003;148:95-101. 
Goudie BM, Wilkieson C, Goudie RB. A family study of vitiligo patterns. Scott Med J 1983; 
28: 338-42. 
Goudie BM, Wilkieson C, Goudie RB. Skin maps in vitiligo. Scott Med J 1983;28:343-6.  
Grunnet I, Howitz J, Reymann F, Schwartz M. Vitiligo and pernicious anemia. Arch 
Dermatol 1970;101:82-5.  
Hafez M, Sharaf L, El-Nabi SMA. The genetics of vitiligo. Acta Derm Venereol. 1983;63:249–51. 
Halder R, Taliaferro S. Vitiligo. In: Wolff K, Goldsmith L, Katz S, Gilchrest B, Paller A, Lefell 
D, eds. Fitzpatrick's Dermatology in General Medicine. Vol 1. 7th ed. New York, 
NY: McGraw-Hill; 2008:72. 
Halder RM. Childhood Vitiligo. Clin Dermatol 1997;15:899-906. 
Handa S, Dogra S. Epidemiology of childhood vitiligo: A study of 625 patients from North 
India. Pediatr Dermatol 2003;20:207-10. 
Handa S, Kaur I. Vitiligo - Clinical findings in 1436 patients. J Dermatol Tokyo 1999; 26: 653-7. 
Hann SK, Lee HJ. Segmental vitiligo, clinical findings in 208 patients. J Am Acad Dermatol 
1996;35:671-4. 
www.intechopen.com
 
Vitiligo – Management and Therapy 28
Hann SK, Lee HJ. Segmental vitiligo: clinical findings in 208 patients. J Am Acad Dermatol 
1996;35: 671-4. 
Hann S-K, Nordlund J (2000) Vitiligo: a comprehensive monograph on basic and clinical 
science. Blackwell Science, Oxford, United Kingdom. 
Hann SK, Park YK, Chun WH. Clinical feature of vitiligo. Clin Dermatol 1997;15:891-7. 
Howitz J, Brodthagen H, Schwartz M, Thomsen K. Prevalence of vitiligo: Epidemiological 
survey the Isle of Bornholm, Denmark. Arch Dermatol 1977; 113: 47-52. 
Jaigirdar MQ, Alam SM, Maidul AZ. Clinical presentation of vitiligo. Mymensingh Med J 
2002;11:79-81. 
Jeninger CK. Childhood vitiligo. Br J Dermatol 1993;51:25-8. 
Kar PK. Vitiligo: A study of 120 cases. Indian J Dermatol Venereol Leprol 2001;67:302-4. 
Khoo OT. Vitiligo. A review and report of treatment of 60 cases in the general hospital, 
Singapore, from 1954 to 1958. Singapore Med J 1962;3:157-68.  
Kim SM, Chung HS, Hann SK. The genetics of vitiligo in Korean patients. Int J Dermatol. 
1997;37:908–10. 
Koranne RK, Sachdeva KG. Vitiligo. Int J Dermatol 1988;27:676-81. 
Koranne RV, Sehgal VN, Sachdeva KG. Clinical profile of vitiligo in North India. Indian J 
Dermatol Venereol Leprol 1986;52:81-2. 
Kovacs SO. Vitiligo. J Am Acad Dermatol 1998;38:647-66. 
Le Poole C, Boissy RE. Vitiligo. Semin Cutan Med Surg 1997;16:3-14. 
Le Poole IC. Sarangarajan R. Zhao Y. Stennett LS. Brown TL. Sheth P. Miki T. Boissy RE. 
VIT1, a novel gene associated with vitiligo. Pigment Cell Res 2001; 14: 475-84. 
Lerner AB. Vitiligo. J Invest Dermatol 1959;32:285-310. 
Lerner MR, Fitzpatrick TB, Halder RM, Hawk JL. Discussion of a case of vitiligo. 
Photodermatol Photoimmunol Photomed 1999;15:41-4.  
Levai M. A study of certain contributory factors in the development of vitiligo in South 
Indian patients. AMA Arch Derm 1958;78:364-71. 
Majumder PP, Das SK, Li CC. A genetical model for vitiligo. Am J Hum Genet. 1988;43:119–
25. 
Majumder PP, Nordlund JJ, Nath SK. Pattern of familial aggregation of vitiligo. Arch 
Dermatol 1993; 129: 994-8. 
Majumder PP. Genetics and prevalence of vitiligo vulgaris. In: Hann SK, Nordlund JJ, 
editors. Vitiligo. Oxford: Blackwell Science; 2000. p. 18–20. 
Mason CP and Gawk Rodger DJ (2005) Vitiligo presentation in adults. Clin Exp Dermatol. 
2005 Jul; 30(4):344-5. 
Mehta NR, Shah KC, Theodore C, Vyas VP, Patel AB (1973) Epidemiological study of 
vitiligo in Surat area. Indian J Med Res 61:145–154. 
Moscher DB, Fitzpatrick TB, Hori Y, Ortonne JP. Disorders of pigmentation. In : Fitzpatick 
TB, Isen AZ, Wolff K, Freedberg IM, Austen KF, editors. Dermatology in general 
medicine. New York: McGraw Hill; 1993. p. 903. 
Mosher DB, Fitzpatrick TB, Ortanne JB. Disorders of pigmentation, hypomelanoses and 
hypermelanoses, In: Freedberg IM, Eisen AZ, Fitzpatrick TB, editors. Dermatology 
in general medicine. 5th ed. New York: McGraw-Hill; 1999. p. 936–45. 
Mosher DM, Fitzpatrick TB, et al. Disorders of pigmentation. In: Fitzpatrick TB, Eisen AZ, 
Wolft K, et al, editors. Dermatology in general medicine. New York: McGraw Hill 
Company, 1987;810-21. 
www.intechopen.com
 
Genetic Epidemiology and Heritability of Vitiligo 29 
Nath SK, Kelly JA, Namjou B, Lam T, Bruner GR, Scofield RH, Aston CE, Harley JB (2001) 
Evidence for a susceptibility gene, SLEV1, on chromosome 17p13 in families with 
vitiligo-related systemic lupus erythematosus. Am J Hum Genet 69:1401–1406. 
Nath SK, Majumder PP, Nordlund JJ. Genetic epidemiology of vitiligo: multilocus 
recessivity cross-validated. Am J Hum Genet. 1994;55:981–90. 
Njoo MD, Westerhof W. Vitiligo: Pathogenesis and treatment. AmJ Clin Dermatol 
2001;2:167–181. 
Nordlund JJ, Lerner AB. Vitiligo-it is important. Arch Dermatol 1982;118:5-8. 
Nordlund JJ, Majumder PP. Recent investigations in vitiligo vulgaris. Dermatol Clin. 
1997;15:69–78. 
Ongenae K, Van Geel N, Naeyaert JM (2003) Evidence for an autoimmune pathogenesis of 
vitiligo. Pigment Cell Res 16:90–100 
Onunu AN, Kubeyinje EP. Vitiligo in the Nigerian African: a study of 351 patients in Benin 
City, Nigeria. Int J Dermatol. 2003 Oct; 42(10):800-2. 
Pajvani U, Ahmad N, Wiley A, Levy RM, Kundu R, Mancini AJ, Chamlin S, Wagner A, 
Paller AS. The relationship between family medical history and childhood vitiligo. 
J Am Acad Dermatol. 2006 Aug; 55(2):238-44. 
Panja G. Leukoderma. Indian J Vener Dis 1947;13:56-63. 
Perrot H. Vitiligo, Thyreopallisis et autominunization. Lyon. Med 1973;30:325-31. 
Poojary SA. Vitiligo and associated autoimmune disorders: A retrospective hospital-based 
study in Mumbai, India. Allergol Immunopathol (madr) 2011 Apr 5. [Epub ahead 
of print].  
Prahalad S. Kingsbury DJ. Griffin TA. Cooper BL. Glass DN. Maksymowych WP. Colbert 
RA. Polymorphism in the MHC- encoded LMP7 gene: association with JRA 
without functional significance for immunoproteasome assembly. J Rheumatol 
2001; 28: 2320-5. 
Punshi SK, Thakre RD. Skin survey. Maharashtra Med J 1969;16: 535-6. 
Ramaiah A, Mojamdar MV, Amarnath VM. Vitiligo in the SSK community of Bangalore. 
Indian JDermatol Veneroel Lepr 1988; 54: 251-4. 
Rezaei N, Gavalas NG, Weetman AP et al. (2007) Autoimmunity as an aetiological factor in 
vitiligo. J Eur Acad Dermatol Venereol 21:865–76. 
Ruiz-Maldonado R, Tamayo Sanchez L, Velazquez E. Epidemiology of skin diseases in 
10,000 patients of pediatric age. Bol Med Hosp Infant Max 1977;34:137-61. 
Sarin RC, Kumar AS. A clinical study of vitiligo. Indian J Dermatol Venereol Lepr 
1977;83:190-194. 
Sehgal VN. A clinical evaluation of 202 cases of Vitiligo. Cutis 1974;14:439-45.  
Shah H, Mehta A, Astik B. Clinical and sociodemographic study of vitiligo. Indian J 
Dermatol Venereol Leprol 2008;74:701. 
Shajil EM, Agrawal D, Vagadia K, Marfatia YS, Begum R. Vitiligo: Clinical profiles in 
Vadodara, Gujarat. Indian J Dermatol 2006;51:100-4. 
Shwartz RA, Janniger CK. Vitiligo. Cutis 1997;60:239-44. 
Singh M, Singh G, Kanwar AJ, Belhaj MS. Clinical pattern of vitiligo in Libya. Int J Dermatol. 
1985;24:233–5. 
Spritz RA (2007). The genetics of generalized vitiligo and associated autoimmune diseases. 
Pigment Cell Res 20:271–8 
Spritz RA (2008) The genetics of generalized vitiligo. Curr Dir Autoimmun 10:244–57. 
www.intechopen.com
 
Vitiligo – Management and Therapy 30
Spritz RA, Gowan K, Bennett DC, Fain PR (2004) Novel vitiligo susceptibility loci on 
chromosomes 7 (AIS2) and 8 (AIS3), confirmation of SLEV1 on chromosome 17, 
andtheir roles in an autoimmune diathesis. Am J Hum Genet 74:188–191. 
Srivastava G. Vitiligo- Introduction Asian Clinic. Dermatol 1994;1:1-5. 
Sun X, Xu A, Wei X, Ouyang J, Lu L, Chen M, Zhang D. Genetic epidemiology of vitiligo: a 
study of 815 probands and their families from south China. Int J Dermatol. 2006 
Oct;45(10):1176–81. 
Tawade YV, Parakh AP, Bharatia PR, Gokhale BB, Ran. Vitiligo : a study of 998 cases 
attending KEM Hospital in Pune. Indian J Dermatol Venereol Leprol 1997;63:95-8. 
Tursen U. Kaya TI. Erdal ME. Derici E. Gunduz O. Ikizoglu G. Association between 
catechol-Omethyltransferase polymorphism and vitiligo. Arch Dermatol Res 2002; 
294: 143-6. 
Westerhof W, Bolhaar B, Menke HE, et al. Resultaten van een enquete onder vitiligo 
patienten. Ned Tjdschr Dermatol Venereol 1996;6:100–105. 
Westerhof W. Vitiligo-a window in the darkness. Dermatology 1995;190:181-2. 
Wittke-Thompson JK, Ambrose N, Yairi E et al. (2007) Genetic studies of stuttering in a 
founder population. J Fluency Disord 32:33–50 
Wright AF, Carothers AD, Pirastu M (1999) Population choice in mapping genes for 
complex diseases. Nat Genet 23:397–404 
Xu YY, Ye DQ, Tong ZC, Hao JH, Jin J, Shen SF, Li CR, Zhang XJ (2002) An epidemiological 
survey for four skin diseases in Anhui [In Chinese]. Chin J Dermatol 35:406–407. 
Zaima H, Koga M. Clinical course of 44 cases of localized type vitiligo. J Dermatol 
2002;29:15-9. 
Zamani M, Spaepen M, Sghar SS, Huang C, Westerhof W, Nieuweboer-Krobotova L, 
Cassiman JJ. Linkage and association of HLA class II genes with vitiligo in a Dutch 
population. Br J Dermatol 2001; 145: 90-4. 
Zeglaoui F, Souissi A, Ben Ayed A, Fazaa B, Kamoun MR. Epidemiological and clinical 
profile of vitiligo in Tunisia: retrospective study of 503 cases. Tunis Med. Dec; 
85(12):1016-9. 
Zhang XJ. Clinical profiles of vitiligo in China: an analysis of 3742 patients. Clin Exp 
Dermatol. 2005;30:327–31. 
Zhang Z, Xu SX, Zhang FY, Yin XY, Yang S, Xiao FL, et al. The analysis of genetics and 
associated autoimmune diseases in Chinese vitiligo patients. Arch Dermatol Res. 
2008 Oct 7. 
www.intechopen.com
Vitiligo - Management and Therapy
Edited by Dr. Kelly KyungHwa Park
ISBN 978-953-307-731-4
Hard cover, 174 pages
Publisher InTech
Published online 14, December, 2011
Published in print edition December, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Vitiligo: Management and Therapy is a practical guide to vitiligo that reflects current research related to the
fundamentals of vitiligo and its management. Vitiligo experts and researchers from all over the world have
contributed to this text, accounting for its comprehensive nature and diverse array of topics. The recent
advances in medicine and technology have led to a better understanding of the disease and have broadened
available treatment options. The essentials are captured in this book and are complemented by useful clinical
photographs and reference tables. This concise tool will serve as an invaluable resource for clinicians in daily
practice.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Abdullateef A. Alzolibani, Ahmad Al Robaee and Khaled Zedan (2011). Genetic Epidemiology and Heritability
of Vitiligo, Vitiligo - Management and Therapy, Dr. Kelly KyungHwa Park (Ed.), ISBN: 978-953-307-731-4,
InTech, Available from: http://www.intechopen.com/books/vitiligo-management-and-therapy/genetic-
epidemiology-and-heritability-of-vitiligo
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
